Is Sun Pharmaceutical (SUNPHARMA) overvalued or fairly valued?

MarketChacha shows Sun Pharmaceutical's valuation in context — a forward P/E of about 30.7, a price-to-book of about 5.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Sun Pharmaceutical's revenue?

Sun Pharmaceutical reported revenue of ₹58,462 Cr for FY2026, with net profit of ₹11,479 Cr, per official filings.

What is the share price of Sun Pharmaceutical (SUNPHARMA)?

Sun Pharmaceutical last traded at ₹1,989.90 (+0.8% on the day), as of 7/29/2026 — a delayed quote shown for education, not investment advice.

Sun Pharmaceutical

SUNPHARMA · NSE · Pharma · India

Snapshot

TickerSUNPHARMA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees47,000

HeadquartersMumbai, India

Websitesunpharma.com

Filings tracked13

About Sun Pharmaceutical

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Who owns it

Promoters55.6%
Institutions28.7%
Public & other15.7%

296 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend19.3% → 19.6%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 10% · PAT 11%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹16,024 Cr · EPS 13.40

Est. earnings growth +3.1%

Next fiscal year

Rev ₹72,970 Cr · EPS 64.28

Est. earnings growth +17.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Revenue (FY2026)

₹58,462 Cr

Net margin

19.6%

Revenue CAGR (3y)

+10.0%

Profit CAGR (3y)

+10.6%

Net profit (FY2026)

₹11,479 Cr

Ask MarketChacha about SUNPHARMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about SUNPHARMA

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹58,462 Cr	₹11,479 Cr	19.6%
FY2025	₹52,578 Cr	₹10,929 Cr	20.8%
FY2024	₹48,497 Cr	₹9,576 Cr	19.7%
FY2023	₹43,886 Cr	₹8,474 Cr	19.3%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹14,612 Cr	₹2,714 Cr	18.6%
2025Q4	₹15,521 Cr	₹3,369 Cr	21.7%
2025Q3	₹14,478 Cr	₹3,118 Cr	21.5%
2025Q2	₹13,851 Cr	₹2,279 Cr	16.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Sun Pharma Advanced Research Company Ltd - 532872 - Intimation For Receipt Of Requests For Reclassification Of Shareholder Category
Intimation for Receipt of Request for Reclassification of Shareholder Category
BSE7/27/2026
Press Release / Media Release
Sun Pharma notes Organon Shareholder approval for proposed acquisition
BSE7/24/2026
Sun Pharma Advanced Research Company Ltd - 532872 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for FY 26
BSE7/16/2026
Sun Pharma Advanced Research Company Ltd - 532872 - Notice Of 21St Annual General Meeting To Be Held On August 10, 2026 Along With The Annual Report For FY 26
Notice of 21st Annual General Meeting along with the Annual Report for FY 26
BSE7/16/2026material
Sun Pharma Advanced Research Company Ltd - 532872 - Reg. 34 (1) Annual Report.
Annual Report 2025-26 and the Notice of 21st Annual General Meeting
BSE7/16/2026
Press Release / Media Release
Press Release
BSE7/15/2026
Notice Of 34Th Annual General Meeting To Be Held On 31 July 2026 Along With The Annual Report For FY 2025-26
Notice of 34th Annual General Meeting along with the Annual Report for FY 2025-26
BSE7/6/2026material
Reg. 34 (1) Annual Report.
Annual Report 2025-26 and the Notice of 34th Annual General Meeting
BSE7/6/2026
Sun Pharma Advanced Research Company Ltd - 532872 - Intimation Regarding 21St Annual General Meeting Of The Company
21st Annual General Meeting of the Company
BSE7/6/2026material
Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation regarding Change in Senior Management Team of the Company
BSE6/26/2026
Sun Pharma Advanced Research Company Ltd - 532872 - Termination Of License Agreement With CMS Bridging DMCC
Termination of License Agreement with CMS Bridging DMCC
BSE6/25/2026
Acquisition
Acquisition of Innovcare Lifesciences Private Limited
BSE6/20/2026material
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015
As attached
BSE6/14/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.